Company Filing History:
Years Active: 2018
Title: Celine Latouche: Innovator in Biomarkers of Mineralocorticoid Receptor Activation
Introduction
Celine Latouche is a prominent inventor based in Melbourne, Victoria, Australia. She has made significant contributions to the field of medical research, particularly in the area of biomarkers related to mineralocorticoid receptor activation. Her work has the potential to enhance treatment strategies for patients requiring specific medical interventions.
Latest Patents
Celine Latouche holds a patent for her invention titled "Biomarkers of Mineralocorticoid Receptor Activation." This patent focuses on the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers for predicting the responsiveness of patients to treatments involving mineralocorticoid receptor antagonists or aldosterone synthase inhibitors. The method involves determining the expression levels of the NGAL gene and/or the SERPINA3 gene in biological samples obtained from patients. She has 1 patent to her name.
Career Highlights
Celine Latouche is affiliated with the Institut National de la Santé et de la Recherche Médicale, where she continues her research and development efforts. Her innovative work has positioned her as a key figure in the exploration of biomarkers that can significantly impact patient care and treatment outcomes.
Collaborations
Celine has collaborated with notable researchers in her field, including Frederic Jaisser and Nicolette Farman. These collaborations have further enriched her research and contributed to advancements in understanding mineralocorticoid receptor activation.
Conclusion
Celine Latouche is an influential inventor whose work on biomarkers for mineralocorticoid receptor activation is paving the way for improved patient treatment strategies. Her contributions to medical research are invaluable and continue to inspire advancements in the field.